Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Duzallo Approval Opens Gout Opportunity For Ironwood

Mon, 08/21/2017 - 3:09pm

Pricing for Duzallo, a fixed-dose combination of Zurampic (lesinurad) with generic allopurinol, will likely be on par with Zurampic's solo...

      Related Stories 

Duzallo Approval Opens Gout Opportunity For Ironwood

Mon, 08/21/2017 - 3:09pm

Pricing for Duzallo, a fixed-dose combination of Zurampic (lesinurad) with generic allopurinol, will likely be on par with Zurampic's solo...

      Related Stories 

Destiny Pharma Seeks AIM Listing To Advance First-In-Class Antibiotics

Mon, 08/21/2017 - 9:27am

UK-based Destiny Pharma hopes its planned IPO will attract investor demand, backed by its promise of new anti-microbial drugs and...

      Related Stories 

AZ Makes Fresh mRNA Move With Ethris Respiratory Pact

Mon, 08/21/2017 - 7:18am

A long-time player in messenger RNA through its partnership with Moderna Therapeutics, AstraZeneca has paid €25m upfront to a German...

      Related Stories 

Pipeline Watch: Phase III Progress With Semaglutide, Sotagliflozin

Mon, 08/21/2017 - 7:02am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

Novartis Starts 'Complex' Trial of Novel Malaria Therapy

Mon, 08/21/2017 - 6:56am

A Phase IIb study of Novartis's first-in-class malaria treatment will take in African and Asian sites, patients of all ages...

      Related Stories 

Samsung Looks Beyond Biosimilars Via Takeda Tie-Up

Mon, 08/21/2017 - 4:33am

Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda. The partners...

      Related Stories 

Finance Watch: 2Q Brings Cost Cuts, Strategic Reviews For Many Biotechs

Fri, 08/18/2017 - 3:23pm

Peregrine, Ardelyx, Egalet and others reduced expenses and sought alternatives in the second quarter. Also, cell and gene therapy investment...

      Related Stories 

Inside The Lupus Pipeline: Reasons For Optimism

Fri, 08/18/2017 - 10:07am

Several drugs for systemic lupus erythematosus (SLE) and lupus nephritis are in mid-to-late stage development, which could pave the way...

      Related Stories 

Pfizer Upbeat After Bagging Besponsa Approval in US

Fri, 08/18/2017 - 8:34am

It is the first CD22-directed antibody-drug conjugate indicated for relapsed or refractory B-cell precursor acute lymphoblastic leukemia, though sales potential...

      Related Stories 

Minimum Stada Takeover Level Reached Just In Time By Bain And Cinven

Fri, 08/18/2017 - 8:02am

A last-minute surge in shareholder acceptances has pushed Bain and Cinven's €5.4bn takeover offer for Stada Arzneimittel over the finish...

      Related Stories 

J&J’s India TB R&D Alliance – Can It Pull Off Something Special?

Fri, 08/18/2017 - 5:27am

Johnson & Johnson’s tuberculosis R&D partnership with the Institute of Microbial Technology in India aims to develop shorter, simpler and...

      Related Stories 

CRISPR Therapeutics President Sam Kulkarni On Business Development

Fri, 08/18/2017 - 2:55am

CRISPR Therapeutics hopes its partnered lead program in sickle cell disease and beta-thalassemia therapies will generate a product launch within...

      Related Stories 

Lynparza Poised For Growth With Broad Ovarian Cancer Approval

Thu, 08/17/2017 - 4:45pm

AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing...

      Related Stories 

Lynparza Poised For Growth With Broad Ovarian Cancer Approval

Thu, 08/17/2017 - 4:45pm

AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing...

      Related Stories 

Mateon's CA4P Disappoints At Second Interim Analysis, More Data Awaited

Thu, 08/17/2017 - 7:32am

A third interim analysis, in September, may clarify whether Mateon’s vascular disrupting agent is likely to be therapeutically useful as...

      Related Stories 

Appointments: Novo Nordisk, Horizon Pharma, Jounce Therapeutics, Pfenex and Pharmalink

Thu, 08/17/2017 - 6:53am

This week's roundup includes CEO appointments by ProTA and Pfenex with various other high-level appointments by Novo Nordisk, Jounce Therapeutics...

      Related Stories 

Pages